-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17

Benzinga·09/17/2026 10:09:52
语音播报
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Abeona Therapeutics (NASDAQ:ABEO) with a Buy rating and announces Price Target of $17.